Upstream Bio (UPB) Return on Sales (2023 - 2026)

Upstream Bio's Return on Sales history runs 4 years deep, the most recent figure standing at 0.6% for Q1 2026.

• On a quarterly basis, Return on Sales rose 2.0% year-over-year to 0.6% in Q1 2026; TTM through Mar 2026 was 1.46%, a 60.0% decrease from a year earlier, with the FY2025 full-year figure at 1.07%, down 49.0% from the prior year.
• Return on Sales improved to 0.6% in Q1 2026 per UPB's latest filing, from 3.07% in the prior quarter.
• Across five years, Return on Sales topped out at 0.13% in Q3 2023 and bottomed at 3.07% in Q4 2025.
• The 4-year median for Return on Sales is 0.84% (2024), against an average of 1.03%.
• Across the five-year window, Return on Sales plunged 156 bps in 2025 and climbed 2 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 1.17% in 2023, then retreated by 29 bps to 1.51% in 2024, then slumped by 103 bps to 3.07% in 2025, then jumped by 81 bps to 0.6% in 2026.
• Per Business Quant, the three latest UPB Return on Sales figures stand at 0.6% (Q1 2026), 3.07% (Q4 2025), and 1.95% (Q3 2025).